As more Antibody-Drug Conjugates head into the clinic, the next-generation of ADCs looms on the horizon. Next-gen strategies are required to engineer an effective therapeutic combining antibody, payload, linker and conjugation method while ensuring stability, targeted delivery, and limited off-target effects. The “Next-Generation Antibody-Drug Conjugates” conference explores the engineering finesse required to achieve improved therapeutics while adhering to the underlying biology that continually emerges, thus highlighting the path to more potent and efficacious molecules. Case Studies and data will be shared that reveal the ongoing efforts to engineer ADCs, move them into the clinic, and fight cancer along with potentially non-oncological indications.
NEXT-GENERATION STRATEGIES FOR ADCs
KEYNOTE PRESENTATION: How to Build a Diversified Portfolio of Pyrollobenzodiazepine-Based Antibody Drug Conjugates
Patrick Van Berkel, PhD, Senior Vice President, Research and Development, ADC Therapeutics, Ltd.
Effective Management of ADC Development and Clinical Manufacturing Including Outsourcing – A Big Pharma Perspective
Ulrich Rümenapp, PhD, Head, Launch Preparation and Coordination, Bayer AG
ADCs Targeting CD163: A Platform for Modulating Macrophage Activity in Cancer and Inflammation – Preclinical Proof of Concept
Jonas Heilskov Graversen, PhD, Associate Professor, Molecular Medicine, University of Southern Denmark
FIGHTING CANCER WITH ADCs
NBE-002, An Anthracycline-Based Immune-Stimulatory Antibody Drug Conjugate (iADC) Targeting ROR1 for the Treatment of Triple-Negative Breast Cancer
Roger Beerli, PhD, CSO, NBE-Therapeutics AG
Amanitin-Based Antibody-Drug-Conjugates as New Therapeutic Modalities for Cancer Therapy
George Badescu, PhD, Vice President, Scientific Affairs, Heidelberg Pharma AG
MGC018: A Duocarmycin-Based ADC Targeting B7-H3
Deryk Loo, PhD, Director, Targeted Therapeutics and Site Operations, MacroGenics, Inc.
Site-Selective, Serum Stable ADCs by Disulfide Bridging and Cysteine Conjugation
James Baker, PhD, Associate Professor, Chemistry, University College London
Overcoming Limitations of Current Antibody-Drug Conjugates (ADCs) by a Novel Linker Technology
Philipp Spycher, PhD, PSI Founder Fellow, Center for Radiopharmaceutical Sciences (CRS), Paul Scherrer Institute
Exploring Boron Reagents for the Assembly of Functional Bioconjugates
Pedro MP Gois, PhD, Assistant Professor and Group Leader, Pharmaceutical Chemistry and Therapeutics, Faculdade de Farmácia, Universidade de Lisboa
Developing Differentiated Next Generation ADC Therapeutics
Robert Lutz, PhD, CSO, Iksuda Therapeutics
NEXT-GEN ADC ENGINEERING
Drug Conjugates Based on Engineered Affibody Molecules
Torbjörn Gräslund, PhD, Professor, Protein Science, KTH Royal Institute of Technology
Tailoring Antibody Fragment Drug Conjugates for Solid Tumours
Mahendra Deonarain, PhD, CEO and CSO, Antikor Biopharma, Ltd.
DARPin Drug Conjugates (DDC): Combining the Potency of Antibody Drug Conjugates and the Flexible DARPin Architecture
Christian Reichen, PhD, Senior Scientist, Lead Generation, Molecular Partners AG
* The program is subject to change without notice, due to unforeseen reason.